Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation - Wikidata - wikimedia - TriplyDB

Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation

Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation

http://www.wikidata.org/entity/Q33765556

about

How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?Alternative donor transplant of benign primary hematologic disorders Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation Desensitization for solid organ and hematopoietic stem cell transplantation Genetic barriers in transplantation medicine Haploidentical hematopoietic transplantation without T-cell depletion: current status and future perspectives Harnessing adaptive natural killer cells in cancer immunotherapy Successful "in-flight" activation of natural killer cells during long-distance shipping Donor selection in T cell-replete haploidentical hematopoietic stem cell transplantation: knowns, unknowns, and controversies.Haploidentical transplantation: the search for the best donor.Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis.Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.NK cell genotype and phenotype at diagnosis of acute lymphoblastic leukemia correlate with postinduction residual disease.Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.The outcomes of family haploidentical hematopoietic stem cell transplantation in hematologic malignancies are not associated with patient age.Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies.Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide Present and Future of Allogeneic Natural Killer Cell Therapy HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients.KIR Genes and Patterns Given by the A Priori Algorithm: Immunity for Haematological Malignancies.Genetics of graft-versus-host disease: the major histocompatibility complex.Killer Cell Immunoglobulin-Like Receptor-Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid Leukemia Strategies in haploidentical stem cell transplantation in adults.Overview of the progress on haploidentical hematopoietic transplantation.Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer.Natural killer cell education and tolerance.The great debate: haploidentical or cord blood transplant.Infusion of allogeneic natural killer cells in a patient with acute myeloid leukemia in relapse after haploidentical hematopoietic stem cell transplantation.Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.Use of NK cell activity in cure by transplant.New strategies for haploidentical transplantation.Immunotherapeutic approaches to treat multiple myeloma Human NK cells: from surface receptors to the therapy of leukemias and solid tumors Experts' considerations on HLA-haploidentical stem cell transplantation.T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor.Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias.Patients Lacking a KIR-Ligand of HLA Group C1 or C2 Have a Better Outcome after Umbilical Cord Blood Transplantation.Bidirectional immune tolerance in nonmyeloablative MHC-mismatched BMT for murine β-thalassemia.

P2860

Q26748867-A1503C5A-B76A-4AEB-84F3-F3B2C43A6E1B Q26823398-3BEFB979-01D5-4F75-8DF1-E9105F82550C Q26852474-4A3585B5-8F8C-435A-BA2F-DBCE05D8E59F Q26863564-29F38357-CAA7-4CF4-8E2D-84AB84C03685 Q28069956-DB5A77B6-DFD5-44C6-AB2D-46636BAE3481 Q28080452-EA084625-22EE-403A-88F2-EEF66C7C4376 Q28081448-64394B71-9B91-4747-A963-549629BB9411 Q33787299-34860BC8-F2B6-4968-A76B-43495775C377 Q33856960-62FE8079-AF66-4FD2-998D-DFE3D7C23501 Q34019548-2F12495C-74E4-417E-BF1E-DDF579AF03B6 Q34088081-B2EDB850-7CEB-451C-B515-A0F57688AC3F Q34175568-B0D40A96-7422-4808-BFE0-E2763C43CD6C Q34193507-EFF6D705-32C5-46C0-A90C-9AEDBA2C4E30 Q34615804-20245F2E-8F9A-492C-B79F-E60811840D83 Q35029441-1605E5D1-1AF1-4F48-A03B-E022C9500BA0 Q35041195-C3041551-A54A-4CE1-8811-ED822248FFA8 Q35083562-57F074C6-C816-40D5-B868-1111F9F560AD Q35478934-14591A50-8AF5-489A-A53A-5D4A67045F43 Q35505839-EB3D0DFE-42AD-4188-B704-A17123CB2A0D Q35677351-D4485E13-F261-42CF-976E-561EECE22019 Q35678422-BD826792-FF74-4A3D-9522-8D821E19A101 Q36163789-2B64F108-B020-4702-90E6-1A2D51D82867 Q36766250-CA8EFA5A-5807-4E02-88F3-16CCEB583F61 Q37024340-201E4147-4C58-49AE-AC77-8FB1D09B359B Q37418956-E9823ECD-0749-4A85-9ABF-FAA1D0A89F18 Q37522577-B7BAC242-1312-44C9-935A-1ADFEC5DF248 Q37590606-D4BE5A22-7B38-4990-8E53-3E286FF4AF4B Q37789866-D424B493-1BD9-4C10-852B-A976AD54FFD5 Q37806066-3E4360C2-4A27-4BF8-83F3-F6976E61DDFE Q37844655-A06917DE-91DF-4BB9-A8D1-C032D4190A7C Q37905034-05A2E9AD-4FFC-4D25-A757-637B2A2265EF Q37910960-AE925730-15D2-49FD-9A13-52FB18CC1021 Q37978777-ADEC1BB2-7472-40EF-8CF8-8FD7AD27505C Q38171067-C9A09DB4-0249-4E00-A544-14196E96DA01 Q38196803-BD9E7655-5E62-4FAB-BB66-1B07B8ED83F5 Q38198728-CB79AFE7-2834-4321-BA49-57A2ED5C5E66 Q38212957-A09E304B-469E-4597-870C-5599D6AD1890 Q38569646-965F7A06-62C2-4859-ADEA-225493947187 Q38656322-DE1CEFB7-5FA2-4643-8700-911A2224B5BE Q38870274-18040862-86C0-46BF-AA3B-8AA56EDADD82

P2860

Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation

http://www.wikidata.org/entity/Q33765556

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Improved survival with inhibit ...... al bone marrow transplantation

@ast

Improved survival with inhibit ...... al bone marrow transplantation

@en

type

label

Improved survival with inhibit ...... al bone marrow transplantation

@ast

Improved survival with inhibit ...... al bone marrow transplantation

@en

prefLabel

Improved survival with inhibit ...... al bone marrow transplantation

@ast

Improved survival with inhibit ...... al bone marrow transplantation

@en

P1433

Q33765556-AD10525B-5B37-408B-8332-48A3A037AD74

P1476

Q33765556-58663B1D-B176-4895-A624-71AC3106349E

P2093

Q33765556-42990782-FCA5-4639-BA51-393EBB512E2C

Q33765556-5F95DB52-5684-47EF-BCF4-081D6667CF52

Q33765556-6A8049F3-4291-435B-B84B-9AA4A8214A7D

Q33765556-B5F5ABB2-BC30-42FE-857D-266E5437EF9E

Q33765556-D1C710EB-9FDD-4EDC-8148-B8BF8124EFF1

Q33765556-ED87C2A6-4BD4-4681-ADD0-808F8B3BA276

P2860

Q33765556-0214E55F-DB1D-47DC-BB15-643A8B81564E

Q33765556-1658B3AF-8EB9-492A-878E-43F6E0A8C204

Q33765556-1703AFF1-7892-4406-87F7-F87F3A206329

Q33765556-2147E0BA-E38E-41F4-85F7-3BFB0F571CCF

Q33765556-22F8A1BC-F47B-4742-90D9-9E398AB290C3

Q33765556-34E618CA-3089-4544-A7AA-C1EF298ED503

Q33765556-3606D09B-FE0D-4531-A145-58EDDE44E0D8

Q33765556-57940D6D-8D35-4B17-AA66-5E3B517D5BDB

Q33765556-58A10B44-CAB8-4F4D-9AB9-0D567C1901EE

Q33765556-5DEA489F-230C-4755-B6A8-B1B17445CEFA

P304

Q33765556-768F4D1B-F511-45A2-AF23-A263344A751A

P31

Q33765556-621693A8-8015-4DAB-B493-15B9F90A8C19

P356

Q33765556-462B2F9A-F12E-44FF-9A10-A8420B494508

P433

Q33765556-0F260255-67C1-45D8-AA09-E3F8E87434B1

P478

Q33765556-193A6544-FF58-45C8-A24A-2B2A82696432

P577

Q33765556-2D16DDD3-1C99-49B4-A1E7-09B5063BD3EE

P5875

Q33765556-703DCC85-B6DD-41D3-93C6-B96895215581

P698

Q33765556-E9B4C77C-028D-4287-9038-9FE26ECA56E0

P921

Q33765556-BDF446F3-AF46-4654-9A38-FC94F42DDE1E

P932

Q33765556-B4D4B64F-08CD-4445-8F06-45B07B2C1D8D

P356

J.BBMT.2009.11.022

P1433

Biology of Blood and Marrow Transplantation

P1476

Improved survival with inhibit ...... al bone marrow transplantation

@en

P2093

Ephraim J Fuchs

http://www.w3.org/2001/XMLSchema#string

Heather J Symons

http://www.w3.org/2001/XMLSchema#string

M Sue Leffell

http://www.w3.org/2001/XMLSchema#string

Marianna Zahurak

http://www.w3.org/2001/XMLSchema#string

Nancy D Rossiter

http://www.w3.org/2001/XMLSchema#string

Richard J Jones

http://www.w3.org/2001/XMLSchema#string

P2860

Statistical aspects of the analysis of data from retrospective studies of disease

Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype

Human diversity in killer cell inhibitory receptor genes

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

The immunobiology of natural killer cells and bone marrow allograft rejection.

Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Immunobiology of natural killer lymphocytes in transplantation.

Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.

Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.

P304

533-542

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBMT.2009.11.022

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40448938

http://www.w3.org/2001/XMLSchema#string

P698

19961944

http://www.w3.org/2001/XMLSchema#string

P921

P932

2848533

http://www.w3.org/2001/XMLSchema#string